A plethora of recent updates:
-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)
-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib
-Pirtobrutinib improves PFS in CLL
-Zanubrutinib has a new dosage form on the way
-Another mitomycin product approved with "reverse thermal properties"
-A new regimen for FL of tafasitamab/rituximab/lenalidomide
-A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options